Advertisement

Topics

Selexis SA and International AIDS Vaccine Initiative (IAVI) Company Profile

19:19 EDT 18th June 2018 | BioPortfolio


News Articles [1993 Associated News Articles listed on BioPortfolio]

IAVI, Selexis SA and Collaborators Publish Study Highlighting Improved Approach for Generating Complex Proteins Required for Producing HIV Vaccines

Paper in Frontiers in Immunology Describes Trimer Design and Development of Production CHO Cell Lines That Generate Properly Folded HIV-1 Env Trimers to Support Goal of Developi...

International AIDS Vaccine Initiative Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12032018] Prices from USD $250

SummaryInternational AIDS Vaccine Initiative IAVI is a notforprofit organization that develops preventive HIV vaccine candidates. The organization offers vaccine development through basic research, di...

Xencor, Selexis Ink CLAs to Advance XmAb Bispecific ADCs

Expanded partnership leverages Selexis’ recombinant therapeutic development solutions

World marks HIV Vaccine Awareness Day – New Vision

New VisionWorld marks HIV Vaccine Awareness DayNew VisionVACCINE FOR HIV. HEALTH- Twenty-one years ago today, Bill Clinton, American president then, said: “It is no longer a question of whether we c...

[Comment] The Lancet Commission on malaria eradication

20 years ago, infectious diseases dominated the global health agenda. Policy makers, researchers, implementers, and donors united in the fight against infectious diseases, creating the Millennium Deve...

NIH Chipping Away at Secrets to AIDS Immunity, Vaccines

New studies by National Institute of Allergy and Infectious Diseases (NIAID) scientists and grantees are helping to fill in pieces of the AIDS vaccine research puzzle...

Xencor extends ‘plug-and-play’ deal with Selexis, signs four mAbs

Xencor and Selexis will extend their strategic partnership with the signing of four commercial license agreements to advance XmAb bispecific antibody drug candidates.

Compugen Licenses Selexis SUREtechnology Platform

Will leverage Selexis’ mammalian cell line-based protein expression platform to develop antibody-based therapeutics

PubMed Articles [2275 Associated PubMed Articles listed on BioPortfolio]

Detection of rotavirus before and after monovalent rotavirus vaccine introduction and vaccine effectiveness among children in mainland Tanzania.

Monovalent rotavirus vaccine (RV1) was introduced in Tanzania in January 2013 under the Reach Every Child initiative, to be given at ages 6 and 10 weeks. We used the sentinel hospital rotavirus surv...

Outside in - inside out. Creating focus on the patient - a vaccine company perspective.

Involving patients in the development of medicines and vaccines should result in benefits to patients. The vaccine recipient is usually a healthy person. We describe the rationale and implementation o...

Increased non-AIDS mortality among persons with AIDS-defining events after antiretroviral therapy initiation.

HIV-1 infection leads to chronic inflammation and to an increased risk of non-AIDS mortality. Our objective was to determine whether AIDS-defining events (ADEs) were associated with increased overall ...

Management of intra-abdominal vascular injury in trauma laparotomy: a South African experience.

Intra-abdominal vascular injury (IAVI) is uncommon but continues to be associated with high mortality rates despite technological advances in the past decades. In light of these ongoing developments, ...

Acute hepatitis A breakthrough in MSM in Paris area: implementation of targeted hepatitis A virus vaccine in a context of vaccine shortage.

Clinical Trials [5216 Associated Clinical Trials listed on BioPortfolio]

Evaluation of the Safety of a Polyvalent Virus in Healthy Adults

This is a research study to evaluate the safety of a vaccine to protect people from HIV infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune Deficiency Syndr...

Development of a New HIV Vaccine

The purpose of the study is to determine the safety of a new HIV vaccine and to evaluate the immune response to the vaccine. Only some HIV genes are used to make the vaccine and therefore...

Mother - Daughter Initiative (MDI) in Cervical Cancer Prevention

The Mother-Daughter Initiative (MDI) will test the feasibility and acceptability of a strategy to deliver comprehensive cervical cancer prevention services in Thailand and the Philippines ...

Safety and Immunogenicity Study of AIDS Vaccine (Combined Use of DNA Vaccine and Recombinant Vaccinia Virus Tiantan)

This trial studies the safety and immunogenicity of a HIV clade B'/C DNA vaccine followed by recombinant vaccinia virus rTV boost in HIV-uninfected healthy volunteers at low or high risk o...

Safety of and Immune Response to Polyvalent HIV-1 Vaccine in HIV Uninfected Adults

This study will evaluate the safety of and immune response to a new HIV vaccine. The vaccine in this trial uses pieces of HIV DNA and HIV proteins. The vaccine itself cannot cause HIV in...

Companies [2019 Associated Companies listed on BioPortfolio]

Selexis SA and International AIDS Vaccine Initiative (IAVI)

IAVI

The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV ...

GlycoMimetics, Inc. and International AIDS Vaccine Initiative and Glycosensors and Diagnostics, LLC

IAVI is a global not-for-profit organization whose mission is to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. Found...

The International AIDS Vaccine Initiative (IAVI)

International AIDS Vaccine Initiative

More Information about "Selexis SA and International AIDS Vaccine Initiative (IAVI)" on BioPortfolio

We have published hundreds of Selexis SA and International AIDS Vaccine Initiative (IAVI) news stories on BioPortfolio along with dozens of Selexis SA and International AIDS Vaccine Initiative (IAVI) Clinical Trials and PubMed Articles about Selexis SA and International AIDS Vaccine Initiative (IAVI) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Selexis SA and International AIDS Vaccine Initiative (IAVI) Companies in our database. You can also find out about relevant Selexis SA and International AIDS Vaccine Initiative (IAVI) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record